ELND005
Description: ELND005 is being investigated as an orally administered treatment for Alzheimer's disease (AD). ELND005 may prevent or inhibit the build up of amyloid protein in the brains of Alzheimer's disease patients.
Study Length: 18 months
Study Requirements: 50 -85 years of age, Diagnosis of Probable AD, Have a reliable stud partner
Contact: Mary Ann Oakley at 412-692-2721
PiB - Pittsburgh Compound B
Description: This study will use PET imaging to determine how amyloid changes across stages of severity in AD and whether amyloid is present in elderly individuals without memory problems.
Study Length: Varies
Study Requirements: 30 years of age or older, Healthy individuals or Diagnosis of Probable AD, or Diagnosis of MCI
Compensation: Up to $200 per year
Contact: Claire McConaha at 412-692-2727
Tolcapone - COMT - Inhibition and Cognitive Enhancement in AD
Description: In this 6-week study we will test whether a drug, called tolcapone, can improve the attention and memory of patients with mild to moderate Alzheimer Disease. Participants will undergo repeated cognitive and behavioral testing and have blood analysis to determine tolerability.
Study Length: 6 weeks
Study Requirements: 50-90 years of age, Diagnosis of Probable AD, Have a reliable study partner
Optional Phase: Patients may continue to take tolcapone following study termination.
Contact: Dr. Robert Sweet at 412-692-2700
Glaucoma Study
Description: Glaucoma is an eye disease that leads to loss of vision. Previous studies have shown a risk of peripheral (side) and central vision problems in patients with Alzheimer’s disease. This study aims to investigate the structures inside of the eye that are involved with peripheral and central vision problems in patients with Alzheimer’s to identify any possible links to glaucoma. Studying this disease and noting the prevalence of glaucoma in AD populations could shed some light on the mechanism and possible treatment modalities for glaucoma.
Study Length: one 60 minute visit (approximate)
Study Requirements: 60 years of age or older; Diagnosis of Alzheimer’s disease
Contact: MaryAnn Oakley at 412-692-2721
Other studies
CEAD Project – Characterizing the Experience of Alzheimer’s Disease
Description: The purpose of this research study is to learn more about suffering in patients with Alzheimer’s disease and related dementias (ADRD), and the impact of patient suffering on family caregivers. The study uses one-on-one interviews with persons who have ADRD and their family members.
Study Length: Initial interviews and follow-up interviews 1 year later
Study Requirements: Spouse, partner or family member of an individual diagnosed with Alzheimer ’s disease or a related dementias
Contact: MaryAnn Oakley at 412-692-2721
SMART Study - Self-Management And Resource Training
Description: This study is designed to determine if a self-management program (educational program) strengthens the personal resources (physical and/or mental) of men and woman living with a family member who has mild memory problems or cognitive impairment.
Study Length: Thirteen months
Study Requirements: Spouse or living partner of an individual diagnosed with Mild Cognitive Impairment (MCI) or dementia.
Contact: MaryAnn Oakley at 412-692-2721
Making Sense of MCI: Patient and Family Perspectives
Description: To learn how those diagnosed with mild cognitive impairment (MCI) and their family members make sense of—or come to terms with—their symptoms and diagnosis
Study Length: A one-time interview lasting approximately 45 minutes
Study Requirements: Individuals diagnosed with MCI who have a family member willing to answer questions about them
Contact: MaryAnn Oakley at 412-692-2721